Tengion completes initial 6M common stock public offering

Tengion, Inc. (Nasdaq: TNGN), a regenerative medicine company focused on discovering, developing, manufacturing and commercializing neo-organs and neo-tissues, today announced the completion of its initial public offering of 6,000,000 shares of common stock at a price of $5.00 per share.  The net proceeds of the offering to Tengion, after deducting underwriting discounts and commissions and estimated offering expenses payable by Tengion, were approximately $26.0 million. In addition, Tengion has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares to cover over-allotments, if any.  The joint book-running managers of the offering are Piper Jaffray & Co. and Leerink Swann LLC.